Wall Street analyst estimates for Healthpeak Properties, Inc. (DOC): consensus price target and buy/hold/sell recommendations.
Healthpeak Properties, Inc. is an S&P 500 constituent operating as a fully integrated real estate investment trust (REIT). The firm is dedicated to the acquisition, management, and development of premier properties essential for both medical research and the provision of healthcare services.
Consensus price target
$22.00 (+16 % vs price $19.03)
between $20.00 and $24.00 · 5 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 19 |
| Hold | 22 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 41 |
| Avg rating (−2 sell to +2 buy) | 0.46 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $0.06 | ||
| 2026-08-04 | $0.08 | $0.03 | +184.2% |
| 2026-05-05 | $0.28 | $0.05 | +430.7% |
| 2026-02-02 | $0.16 | $0.45 | -64.4% |
| 2025-10-23 | $-0.17 | $0.06 | -383.3% |
| 2025-07-24 | $0.05 | $0.06 | -21.9% |
| 2025-04-24 | $0.06 | $0.05 | +11.7% |
| 2025-02-03 | $0.01 | $0.05 | -80.0% |
Valuation Ratios
| P/E Ratio | 54.37 |
| Price / Book | 1.67 |
| EV / EBITDA | 12.49 |
| Dividend Yield | 6.41% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.13B | $1.85B | $1.19B | $1.24B | $1.64B | $1.90B | $2.06B | $2.18B | $2.70B | $2.82B |
| Cost of Revenue | $738.4M | $666.3M | $378.7M | $405.2M | $782.5M | $773.3M | $863.0M | $902.1M | $1.07B | $2.19B |
| Gross Profit | $1.39B | $1.18B | $812.7M | $835.1M | $862.3M | $1.12B | $1.20B | $1.28B | $1.63B | $634.5M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $103.6M | $88.8M | $96.7M | $93.0M | $93.2M | $98.3M | $131.0M | $95.1M | $97.2M | $90.4M |
| Operating Expenses | $671.7M | $623.5M | $501.4M | $528.2M | $647.2M | $782.6M | $841.6M | $845.0M | $1.15B | $90.4M |
| Operating Income | $719.2M | $558.6M | $311.3M | $306.9M | $215.1M | $340.3M | $356.6M | $433.9M | $471.2M | $544.1M |
| EBITDA | $1.40B | $1.25B | $1.65B | $1.05B | $1.13B | $970.6M | $1.39B | $1.27B | $1.61B | $1.44B |
| Interest Expense | $464.4M | $307.7M | $261.3M | $217.6M | $218.3M | $158.0M | $172.9M | $200.3M | $280.4M | $305.2M |
| Pre-tax Income | $378.6M | $421.3M | $832.8M | $170.0M | $151.1M | $134.5M | $509.1M | $325.1M | $271.7M | $110.3M |
| Income Tax | $4.5M | -$1.3M | -$4.4M | -$5.5M | -$9.4M | -$3.3M | -$4.4M | -$9.6M | $4.3M | $9.3M |
| Net Income | $627.7M | $414.2M | $1.06B | $45.5M | $413.6M | $505.5M | $500.4M | $306.0M | $243.1M | $71.3M |
| EPS | $1.34 | $0.88 | $2.25 | $0.09 | $0.77 | $0.93 | $0.92 | $0.56 | $0.36 | $0.10 |
| EPS (Diluted) | $1.34 | $0.88 | $2.24 | $0.09 | $0.77 | $0.93 | $0.92 | $0.56 | $0.36 | $0.10 |
| Shares Outstanding (Diluted) | 467.4 M | 468.9 M | 475.4 M | 489.3 M | 531.1 M | 539.2 M | 539.1 M | 547.3 M | 676.2 M | 696.0 M |
Price
| Price | $19.03 (closing price, October 30, 2026) |
| Market Cap | $13.1B |
| Exchange | NYSE |
| Country | US |
Related companies: SBRA · WELL · OHI · AHR · CTRE · NHI · LTC
Explore sector: Real Estate · REIT - Healthcare Facilities
More sections of DOC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks